Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01

Vaccine

Volumn 27, Issue 6, 2009, Pages 893-903

  Iyer, Arun V ^a   Pahar, Bapi ^b   Boudreaux, Marc J ^a   Wakamatsu, Nobuko ^a   Roy, Alma F ^a   Chouljenko, Vladimir N ^a   Baghian, Abolghasem ^a   Apetrei, Cristian ^b   Marx, Preston A ^b   Kousoulas, Konstantin G ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Humoral and cellular immunity; Mucosal immunization; Vesicular stomatitis virus; Viral vector; West Nile virus

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CD69 ANTIGEN; GAMMA INTERFERON ANTIBODY; GLYCOPROTEIN E; L SELECTIN; VIRUS VECTOR; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BRAIN TISSUE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION; VACCINATION; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS VIRULENCE; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; BRAIN; CRICETINAE; FEMALE; INTERFERON-GAMMA; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VESICULAR STOMATITIS INDIANA VIRUS; VESICULOVIRUS; VIRAL STRUCTURAL PROTEINS; WEST NILE FEVER; WEST NILE VIRUS VACCINES;

EID: 58249118005     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.087     Document Type: Article

References (97)

1. Smithburn K.C., Hughes T.P., Burke A.W., and Paul J.H. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 20 (1940) 471-492
2. Lindenbach B.D., Thiel H.-J., and Rice C.M. Flaviviridae: the viruses and their replication. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields' virology. 5th Edition (2007), Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia 1101-1152
3. Zhang Y., Corver J., Chipman P.R., Zhang W., Pletnev S.V., Sedlak D., et al. Structures of immature flavivirus particles. Embo J 22 June (11) (2003) 2604-2613
4. Zhang Y., Zhang W., Ogata S., Clements D., Strauss J.H., Baker T.S., et al. Conformational changes of the flavivirus E glycoprotein. Structure 12 September (9) (2004) 1607-1618
5. Ledizet M., Kar K., Foellmer H.G., Bonafe N., Anthony K.G., Gould L.H., et al. Antibodies targeting linear determinants of the envelope protein protect mice against West Nile virus. J Infect Dis 196 December (12) (2007) 1741-1748
6. Lanciotti R.S., Roehrig J.T., Deubel V., Smith J., Parker M., Steele K., et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286 December (5448) (1999) 2333-2337
7. CDC. Intrauterine West Nile virus infection--New York, 2002. MMWR Morb Mortal Wkly Rep 2002;51(December (50)):1135-6.
8. CDC. Possible West Nile virus transmission to an infant through breast-feeding--Michigan, 2002. MMWR Morb Mortal Wkly Rep 2002;51(October (39)):877-8.
9. Hayes E.B., and O'Leary D.R. West Nile virus infection: a pediatric perspective. Pediatrics 113 May (5) (2004) 1375-1381
10. CDC. Transfusion-associated transmission of West Nile virus--Arizona, 2004. MMWR Morb Mortal Wkly Rep 2004;53(September (36)):842-4.
11. CDC. Investigations of West Nile virus infections in recipients of blood transfusions. MMWR Morb Mortal Wkly Rep 2002;51(November (43)):973-4.
12. CDC. Detection of West Nile virus in blood donations--United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52(August (32)):769-72.
13. Hiatt B., DesJardin L., Carter T., Gingrich R., Thompson C., and de Magalhaes-Silverman M. A fatal case of West Nile virus infection in a bone marrow transplant recipient. Clin Infect Dis 37 November (9) (2003) e129-e131
14. CDC. West Nile virus infection in organ donor and transplant recipients--Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep 2002;51(September (35)):790.
15. Iwamoto M., Jernigan D.B., Guasch A., Trepka M.J., Blackmore C.G., Hellinger W.C., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 348 May (22) (2003) 2196-2203
16. CDC. Possible dialysis-related west nile virus transmission--Georgia, 2003. MMWR Morb Mortal Wkly Rep 2004;53(August (32)):738-9.
17. Cairoli O. The West Nile Virus and the dialysis/transplant patient. Nephrol News Issues 19 November (12) (2005) 73-75
18. Gea-Banacloche J., Johnson R.T., Bagic A., Butman J.A., Murray P.R., and Agrawal A.G. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 140 April (7) (2004) 545-553
19. Del Giudice P., Schuffenecker I., Zeller H., Grelier M., Vandenbos F., Dellamonica P., et al. Skin manifestations of West Nile virus infection. Dermatology 211 4 (2005) 348-350
20. Ferguson D.D., Gershman K., LeBailly A., and Petersen L.R. Characteristics of the rash associated with West Nile virus fever. Clin Infect Dis 41 October (8) (2005) 1204-1207
21. Davis L.E., DeBiasi R., Goade D.E., Haaland K.Y., Harrington J.A., Harnar J.B., et al. West Nile virus neuroinvasive disease. Ann Neurol 60 September (3) (2006) 286-300
22. Jeha L.E., Sila C.A., Lederman R.J., Prayson R.A., Isada C.M., and Gordon S.M. West Nile virus infection: a new acute paralytic illness. Neurology 61 July (1) (2003) 55-59
23. Kulstad E.B., and Wichter M.D. West Nile encephalitis presenting as a stroke. Ann Emerg Med 41 February (2) (2003) 283
24. Perelman A., and Stern J. Acute pancreatitis in West Nile fever. Am J Trop Med Hyg 23 November (6) (1974) 1150-1152
25. Sampson B.A., Ambrosi C., Charlot A., Reiber K., Veress J.F., and Armbrustmacher V. The pathology of human West Nile virus infection. Hum Pathol 31 May (5) (2000) 527-531
26. Smith R.D., Konoplev S., DeCourten-Myers G., and Brown T. West Nile virus encephalitis with myositis and orchitis. Hum Pathol 35 February (2) (2004) 254-258
27. Khairallah M., Ben Yahia S., Ladjimi A., Zeghidi H., Ben Romdhane F., Besbes L., et al. Chorioretinal involvement in patients with West Nile virus infection. Ophthalmology 111 November (11) (2004) 2065-2070
28. Hayes E.B., Sejvar J.J., Zaki S.R., Lanciotti R.S., Bode A.V., and Campbell G.L. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 11 August (8) (2005) 1174-1179
29. Sejvar J.J. The long-term outcomes of human West Nile virus infection. Clin Infect Dis 44 June (12) (2007) 1617-1624
30. Dauphin G., and Zientara S. West Nile virus: recent trends in diagnosis and vaccine development. Vaccine 25 July (30) (2007) 5563-5576
31. Grosenbaugh D.A., Backus C.S., Karaca K., Minke J.M., and Nordgren R.M. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet Ther 5 Winter (4) (2004) 251-257
32. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 65 November (11) (2004) 1459-1462
33. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 18 (2004) 221-230
34. Karaca K., Bowen R., Austgen L.E., Teehee M., Siger L., Grosenbaugh D., et al. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 23 May (29) (2005) 3808-3813
35. Siger L., Bowen R., Karaca K., Murray M., Jagannatha S., Echols B., et al. Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses. Vet Ther 7 Fall (3) (2006) 249-256
36. Iglesias M.C., Frenkiel M.P., Mollier K., Souque P., Despres P., and Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 8 March (3) (2006) 265-274
37. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., and Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191 January (2) (2005) 207-214
38. Monath T.P. Yellow fever: an update. Lancet Infect Dis 1 August (1) (2001) 11-20
39. Monath T.P. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci 951 December (2001) 1-12
40. Tesh R.B., Arroyo J., Travassos Da Rosa A.P., Guzman H., Xiao S.Y., and Monath T.P. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 8 December (12) (2002) 1392-1397
41. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78 November (22) (2004) 12497-12507
42. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103 April (17) (2006) 6694-6699
43. Hall R.A., and Khromykh A.A. ChimeriVax-West Nile vaccine. Curr Opin Mol Ther 9 October (5) (2007) 498-504
44. Lichty B.D., Power A.T., Stojdl D.F., and Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 10 May (5) (2004) 210-216
45. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 June (6) (1998) 4704-4711
46. Roberts A., Buonocore L., Price R., Forman J., and Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73 May (5) (1999) 3723-3732
47. Schwartz J.A., Buonocore L., Roberts A., Suguitan Jr. A., Kobasa D., Kobinger G., et al. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366 September (1) (2007) 166-173
48. Grigera P.R., Marzocca M.P., Capozzo A.V., Buonocore L., Donis R.O., and Rose J.K. Presence of bovine viral diarrhea virus (BVDV) E2 glycoprotein in VSV recombinant particles and induction of neutralizing BVDV antibodies in mice. Virus Res 69 August (1) (2000) 3-15
49. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 November (22) (2001) 11079-11087
50. Brandsma J.L., Shlyankevich M., Buonocore L., Roberts A., Becker S.M., and Rose J.K. Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine 25 January (4) (2007) 751-762
51. Brandsma J.L., Shylankevich M., Su Y., Roberts A., Rose J.K., Zelterman D., et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J Virol 81 June (11) (2007) 5749-5758
52. Ezelle H.J., Markovic D., and Barber G.N. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol 76 December (23) (2002) 12325-12334
53. Schlereth B., Buonocore L., Tietz A., Meulen Vt V., Rose J.K., and Niewiesk S. Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 84 August (Pt 8) (2003) 2145-2151
54. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 May (10) (2004) 5458-5465
55. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 July (7) (2005) 786-790
56. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Stroher U., Hensley L.E., Grolla A., et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80 October (19) (2006) 9659-9666
57. Daddario-DiCaprio K.M., Geisbert T.W., Stroher U., Geisbert J.B., Grolla A., Fritz E.A., et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367 April (9520) (2006) 1399-1404
58. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2 June (6) (2005) e183
59. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 September (2) (2005) 174-182
60. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80 May (9) (2006) 4447-4457
61. Haglund K., Forman J., Krausslich H.G., and Rose J.K. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268 March (1) (2000) 112-121
62. Johnson J.E., Rodgers W., and Rose J.K. A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions. Virology 251 November (2) (1998) 244-252
63. Johnson J.E., Schnell M.J., Buonocore L., and Rose J.K. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 71 July (7) (1997) 5060-5068
64. Xing Z., and Lichty B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86 May-July (3-4) (2006) 211-217
65. Palin A., Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25 January (4) (2007) 741-750
66. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20 September (9) (2004) 989-1004
67. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 April (8) (2004) 3930-3940
68. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 September (5) (2001) 539-549
69. Iyer AV, Boudreaux MJ, Wakamatsu N, Roy AF, Baghian A, Chouljenko VN, et al. The Louisiana West Nile virus strain LSU-AR01 isolated from a blue jay (Cyanocitta cristata) exhibits increased mouse neurovirulence in comparison to the prototypic New York-99 strain and is closely related to the Connecticut-99 mosquito isolate, Virus Genes, in press.
70. Schnell M.J., Buonocore L., Kretzschmar E., Johnson E., and Rose J.K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci USA 93 October (21) (1996) 11359-11365
71. Schnell M.J., Buonocore L., Whitt M.A., and Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 April (4) (1996) 2318-2323
72. Pahar B., Wang X., Dufour J., Lackner A.A., Veazey R.S., and Virus-specific. T cell responses in macaques acutely infected with SHIV(sf162p3). Virology 363 June (1) (2007) 36-47
73. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75 May (9) (2001) 4040-4047
74. Brines R.D., and Klaus G.G. Polyclonal activation of immature B cells by preactivated T cells: the role of IL-4 and CD40 ligand. Int Immunol 5 November (11) (1993) 1445-1450
75. Sancho D., Gomez M., and Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 26 March (3) (2005) 136-140
76. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 July (7) (2006) 1693-1700
77. Office international des épizooties (Paris) O.I.E. Vesicular stomatitis. Manual of diagnostic tests and vaccines for terrestrial animals 2004. fifth edition (2004), OIE. Office international des épizooties, Paris pp. 129-35
78. Clarke D.K., Cooper D., Egan M.A., Hendry R.M., Parks C.L., and Udem S.A. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer seminars in immunopathology 28 November (3) (2006) 239-253
79. Roche S., Rey F.A., Gaudin Y., and Bressanelli S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315 February (5813) (2007) 843-848
80. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76 September (17) (2002) 8900-8909
81. Publicover J., Ramsburg E., and Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 79 November (21) (2005) 13231-13238
82. Cooper D., Wright K.J., Calderon P.C., Guo M., Nasar F., Johnson J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 82 January (1) (2008) 207-219
83. Rose N.F., Roberts A., Buonocore L., and Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74 December (23) (2000) 10903-10910
84. Grewal I.S., Foellmer H.G., Grewal K.D., Xu J., Hardardottir F., Baron J.L., et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 273 September (5283) (1996) 1864-1867
85. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1 June (3) (1994) 167-178
86. O'Keefe G.M., Nguyen V.T., and Benveniste E.N. Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases. J Neurovirol 8 December (6) (2002) 496-512
87. Brien J.D., Uhrlaub J.L., and Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 37 July (7) (2007) 1855-1863
88. McMurtrey C.P., Lelic A., Piazza P., Chakrabarti A.K., Yablonsky E.J., Wahl A., et al. Epitope discovery in West Nile virus infection: identification and immune recognition of viral epitopes. Proc Natl Acad Sci USA 105 February (8) (2008) 2981-2986
89. Purtha W.E., Myers N., Mitaksov V., Sitati E., Connolly J., Fremont D.H., et al. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 37 July (7) (2007) 1845-1854
90. De Groot A.S., Saint-Aubin C., Bosma A., Sbai H., Rayner J., and Martin W. Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg Infect Dis 7 July-August (4) (2001) 706-713
91. Waters W.R., Rahner T.E., Palmer M.V., Cheng D., Nonnecke B.J., and Whipple D.L. Expression of L-Selectin (CD62L), CD44, and CD25 on activated bovine T cells. Infect Immun 71 January (1) (2003) 317-326
92. Zhang L., and Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 211 June (3) (2007) 590-597
93. Banham A.H. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol 27 December (12) (2006) 541-544
94. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203 July (7) (2006) 1701-1711
95. Wang Y., Lobigs M., Lee E., and Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77 December (24) (2003) 13323-13334
96. Shrestha B., and Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J Virol 78 August (15) (2004) 8312-8321
97. Buonocore L., Blight K.J., Rice C.M., and Rose J.K. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 76 July (14) (2002) 6865-6872